Skip to main content
Caplight Logo









Basgenbio

Basgenbio

Private
SeoulHealthcare & Life Scienceshttps://basgenbio.com/kr/

Last Round

VC Round

Dec 22, 2025

Total Funding Raised

$13.29M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Basgenbio is a biotechnology company that provides biomarker discovery and AI-driven drug development platforms by analyzing clinico-genomic cohort data.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Medical AI, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Subscription SaaS, Government Contracts, Revenue Share

AI Layer

Application

Keywords

drug discoveryclinical trial simulationbiomarker discoveryin silicoprecision medicineclinico-genomic databaseAI drug discoverypatient stratificationdrug response predictionSaaSbiotech AIdigital twintarget discoverypharma tech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Basgenbio Comparables

Compare Basgenbio with similar companies based on industry and business-model similarity.

Basgenbio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
VeriSIM Life
87%
QuantHealth
84%
PharmCADD Co., Ltd.
83%

Basgenbio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundDec 22, 2025
GrantDec 22, 2025
GrantAug 21, 2025
Series BJun 8, 2023
Series AMay 28, 2021
Strategic
May 24, 2021

Key People

Founding team and executive leadership

Yunsu Yang

COO co-founder

Founding Team

Basgenbio Investors

Notable investors and investment history

Basgenbio investors
InvestorRounds
DS Asset ManagementSeries A
Pathfinder HVC Round
CelltrionSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 21, 2026

    Grew 18% QoQ from 17 to 20 employees.

  • Jun 25, 2026

    Grew 31% QoQ, from 16 to 21 employees.

Basgenbio Filings

Explore SEC and related filing metadata, where available.

Basgenbio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Basgenbio's valuation, stock price, and market status.

Is Basgenbio a public or private company?

Basgenbio is a private company.

What is the current stock price of Basgenbio?

Basgenbio is a private company with no public stock price. No recent secondary market data is available.

How much is Basgenbio worth (valuation)?

Valuation information for Basgenbio is not publicly available.

Can I buy Basgenbio stock?

Basgenbio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Basgenbio's last funding round?

Basgenbio's most recent funding round was VC Round on December 22, 2025.

Who are the main investors in Basgenbio?

Key investors in Basgenbio include DS Asset Management.

Will Basgenbio IPO soon?

No public IPO plans have been announced for Basgenbio.

How can I track Basgenbio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Basgenbio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSeoul
Employee Range21
Year Founded2018
Last FundingDec 22, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?